Theravance Biopharma
TBPH
169 hedge funds and large institutions have $927M invested in Theravance Biopharma in 2025 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 72 increasing their positions, 47 reducing their positions, and 18 closing their positions.
15,863% more call options, than puts
Call options by funds: $2.55M | Put options by funds: $16K
53% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 47
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
31% more capital invested
Capital invested by funds: $706M → $927M (+$221M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more funds holding
Funds holding: 162 → 169 (+7)
1.81% more ownership
Funds ownership: 96.06% → 97.87% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$5.62M |
| 2 |
Two Sigma Investments
New York
|
+$5.08M |
| 3 |
Janus Henderson Group
London,
|
+$4.53M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.35M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$3.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$18.3M |
| 2 |
NM
Newtyn Management
New York
|
-$10.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.98M |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$6.5M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$3.05M |
TBPH Hedge Fund Activity: Q4 2025 in Review
169 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2025, worth a combined $927M — up 31% from $706M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TBPH positions and 18 closed out — a net gain of 9 holders — while 72 added to existing stakes and 47 trimmed.
The largest buyer was Pacer Advisors, opening a new position worth an estimated $5.62M. The largest seller was Park West Asset Management, cutting an estimated $18.3M.
- 169 institutional investors held Theravance Biopharma (TBPH) as of Q4 2025, up from 162 in Q3 2025.
- Funds reported $927M of Theravance Biopharma stock for Q4 2025, up 31% quarter-over-quarter.
- 27 funds opened new Theravance Biopharma positions in Q4 2025 and 18 closed out, a net change of +9 holders.
- The largest Theravance Biopharma buyer in Q4 2025 was Pacer Advisors, an estimated $5.62M added.
- The largest Theravance Biopharma seller in Q4 2025 was Park West Asset Management, an estimated $18.3M sold.
Based on aggregated 13F filings for Q4 2025.